Atea Pharmaceuticals (AVIR) EBITDA Margin (2021)
Atea Pharmaceuticals (AVIR) posted quarterly EBITDA Margin of 63.06% for Q4 2021, up 193.42% quarter-over-quarter from 67.5% in Q3 2021.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) EBITDA Margin (2021) Analysis & Trends
Atea Pharmaceuticals' EBITDA Margin history runs 1 years deep, the most recent figure standing at 63.06% for Q4 2021.
- In Q4 2021, EBITDA Margin changed N/A year-over-year to 63.06%; the TTM figure through Dec 2021 stood at 39.38% (changed N/A YoY), while the FY2021 annual figure was 39.38%, up 6206.0% from the prior year.
- EBITDA Margin for Q4 2021 stood at 63.06%, up from 67.5% in the prior quarter.
- The five-year high for EBITDA Margin was 63.06% in Q4 2021, with the low at 67.5% in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 10 | Atea Pharmaceuticals | 469.10 Mn | 469.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 63.06% |
| Sep 30, 2021 | -67.50% |
| Jun 30, 2021 | 14.38% |
| Mar 31, 2021 | 46.46% |